A new QIMR Berghofer study has added weight to the potential benefits of using ultrasound treatment to deliver disease-targeting drugs to Alzheimer’s patients.
The study is the first to examine the technique on brain cells derived from human patients with Alzheimer’s disease, building on previous research on mice and other animal models.
The findings have been published today in the journal Stem Cell Reports.
Lead Australian researcher and head of QIMR Berghofer’s Cellular and Molecular Neurodegeneration group, Associate Professor Anthony White, said the researchers found using focused ultrasound coupled with microbubble treatment,…
